200 related articles for article (PubMed ID: 24347976)
1. Pharmacovigilance in Italy: An overview.
Mazzitello C; Esposito S; De Francesco AE; Capuano A; Russo E; De Sarro G
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S20-8. PubMed ID: 24347976
[TBL] [Abstract][Full Text] [Related]
2. Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis.
Scicchitano F; Giofrè C; Palleria C; Mazzitello C; Ciriaco M; Gallelli L; Paletta L; Marrazzo G; De Fazio S; Menniti M; Curia R; Arena C; Chimirri S; Patanè M; Esposito S; Cilurzo F; Staltari O; Russo E; De Sarro G
J Res Med Sci; 2012 Sep; 17(9):872-5. PubMed ID: 23826016
[TBL] [Abstract][Full Text] [Related]
3. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
4. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
[TBL] [Abstract][Full Text] [Related]
5. Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis.
Giofrè C; Scicchitano F; Palleria C; Mazzitello C; Ciriaco M; Gallelli L; Paletta L; Marrazzo G; Leporini C; Ventrice P; Carbone C; Saullo F; Rende P; Menniti M; Mumoli L; Chimirri S; Patanè M; Esposito S; Cilurzo F; Staltari O; Russo E; De Sarro G;
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S55-60. PubMed ID: 24347984
[TBL] [Abstract][Full Text] [Related]
6. Informatics applied to pharmacovigilance: Future perspectives.
Menniti M; Menniti A; Patanè M; Esposito S; Giofrè C; Aiello R; Russo E
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S43-6. PubMed ID: 24347981
[TBL] [Abstract][Full Text] [Related]
7. Pharmacovigilance and the italian medicines agency.
Pimpinella G; Tartaglia L
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S4-6. PubMed ID: 24347980
[TBL] [Abstract][Full Text] [Related]
8. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance.
Monaco L; Melis M; Biagi C; Donati M; Sapigni E; Vaccheri A; Motola D
Expert Opin Drug Saf; 2017 Mar; 16(3):271-275. PubMed ID: 28094583
[TBL] [Abstract][Full Text] [Related]
9. FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients.
Fracchiolla NS; Artuso S; Cortelezzi A; Pelizzari AM; Tozzi P; Bonfichi M; Bocchio F; Gargantini L; De Rosa E; Vighi GD; Prestini L; Sammassimo S; Frungillo N; Pasquini MC; Ragazzi A; Boghi D; Pastore A; Lanzi E; Gritti G; Quaresmini G; Voltolini S; Gaiardoni R; Corti C; Vilardo MC; La Targia ML; Berini G; Magagnoli M; Bacci C; Consonni D; Rivolta AL; Muti G
Hematol Oncol; 2018 Feb; 36(1):299-306. PubMed ID: 28771763
[TBL] [Abstract][Full Text] [Related]
10. Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among healthcare professionals in Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia.
Abdel-Latif MM; Abdel-Wahab BA
Saudi Pharm J; 2015 Apr; 23(2):154-61. PubMed ID: 25972735
[TBL] [Abstract][Full Text] [Related]
11. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
[TBL] [Abstract][Full Text] [Related]
12. Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network.
Gozzo L; Navarria A; Benfatto G; Longo L; Mansueto S; Sottosanti L; Pani L; Salomone S; Drago F
Clin Drug Investig; 2017 Nov; 37(11):1067-1081. PubMed ID: 28856572
[TBL] [Abstract][Full Text] [Related]
13. Knowledge, attitudes and practice regarding pharmacovigilance and adverse drug reaction reporting among physicians and pharmacists in Egypt: a step toward personalized medicine implementation.
Aziz AA; Rogers S; Hassanien O; Shalaby L; Nagy M
Per Med; 2022 Nov; 19(6):495-507. PubMed ID: 36239598
[TBL] [Abstract][Full Text] [Related]
14. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme.
Carnovale C; Gentili M; Fortino I; Merlino L; Clementi E; Radice S; ViGer Group
Expert Opin Drug Saf; 2016; 15(2):131-9. PubMed ID: 26882049
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
[TBL] [Abstract][Full Text] [Related]
16. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
Matos C; van Hunsel F; Joaquim J
Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
[TBL] [Abstract][Full Text] [Related]
17. Nexavar(®)-related adverse reactions: Calabrian (Italy) experience for sorafenib exposition in 2012.
Cilurzo F; Staltari O; Patanè M; Ammendola M; Garaffo C; Di Paola ED
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S86-9. PubMed ID: 24347990
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
19. [Safety and tolerability of psychotropic medications in childhood: preliminary data of a pharmacovigilance study].
Magazù A; Masi G; Germanò E; Gagliostro MS; Siracusano R; Arcoraci V; Spina E; Gagliano A
Minerva Pediatr; 2014 Jun; 66(3):187-99. PubMed ID: 24826975
[TBL] [Abstract][Full Text] [Related]
20. Effect of pharmacist involvement on patient reporting of adverse drug reactions: first Italian study.
Leone R; Moretti U; D'Incau P; Conforti A; Magro L; Lora R; Velo G
Drug Saf; 2013 Apr; 36(4):267-76. PubMed ID: 23475583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
